boston scientific corp. - BSX

BSX

Close Chg Chg %
68.16 1.63 2.38%

Closed Market

69.78

+1.63 (2.38%)

Volume: 9.44M

Last Updated:

Mar 25, 2026, 3:59 PM EDT

Company Overview: boston scientific corp. - BSX

BSX Key Data

Open

$68.90

Day Range

68.60 - 70.10

52 Week Range

67.56 - 109.50

Market Cap

$101.13B

Shares Outstanding

1.48B

Public Float

1.48B

Beta

0.69

Rev. Per Employee

N/A

P/E Ratio

35.15

EPS

$1.96

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

12.95M

 

BSX Performance

1 Week
 
-1.91%
 
1 Month
 
-11.32%
 
3 Months
 
-29.05%
 
1 Year
 
-31.41%
 
5 Years
 
78.31%
 

BSX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 37
Full Ratings ➔

About boston scientific corp. - BSX

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

BSX At a Glance

Boston Scientific Corp.
300 Boston Scientific Way
Marlborough, Massachusetts 01752-1234
Phone 1-508-683-4000 Revenue 20.07B
Industry Medical Specialties Net Income 2.90B
Sector Health Technology 2025 Sales Growth 19.866%
Fiscal Year-end 12 / 2026 Employees 59,000
View SEC Filings

BSX Valuation

P/E Current 35.862
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 49.172
Price to Sales Ratio 7.099
Price to Book Ratio 5.835
Price to Cash Flow Ratio 31.43
Enterprise Value to EBITDA 28.069
Enterprise Value to Sales 7.605
Total Debt to Enterprise Value 0.078

BSX Efficiency

Revenue/Employee 340,237.288
Income Per Employee 49,118.644
Receivables Turnover 6.861
Total Asset Turnover 0.483

BSX Liquidity

Current Ratio 1.617
Quick Ratio 1.076
Cash Ratio 0.376

BSX Profitability

Gross Margin 65.039
Operating Margin 20.28
Pretax Margin 16.863
Net Margin 14.437
Return on Assets 6.977
Return on Equity 12.599
Return on Total Capital 8.004
Return on Invested Capital 8.657

BSX Capital Structure

Total Debt to Total Equity 49.404
Total Debt to Total Capital 33.067
Total Debt to Total Assets 27.413
Long-Term Debt to Equity 47.798
Long-Term Debt to Total Capital 31.993
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Boston Scientific Corp. - BSX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
12.68B 14.24B 16.75B 20.07B
Sales Growth
+6.68% +12.29% +17.61% +19.87%
Cost of Goods Sold (COGS) incl D&A
4.97B 5.41B 6.48B 7.02B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.14B 1.20B 1.27B 1.37B
Depreciation
333.00M 368.00M 413.00M 471.00M
Amortization of Intangibles
803.00M 828.00M 856.00M 897.00M
COGS Growth
+12.22% +8.88% +19.80% +8.30%
Gross Income
7.71B 8.83B 10.27B 13.06B
Gross Income Growth
+3.39% +14.48% +16.26% +27.16%
Gross Profit Margin
+60.83% +62.02% +61.31% +65.04%
2022 2023 2024 2025 5-year trend
SG&A Expense
5.84B 6.60B 7.60B 8.94B
Research & Development
1.32B 1.41B 1.61B 2.05B
Other SG&A
4.52B 5.19B 5.98B 6.89B
SGA Growth
+6.43% +13.02% +15.07% +17.63%
Other Operating Expense
47.00M 46.00M 33.00M 46.00M
Unusual Expense
417.00M 71.00M 32.00M 533.00M
EBIT after Unusual Expense
1.41B 2.11B 2.60B 3.54B
Non Operating Income/Expense
198.00M 147.00M 66.00M 171.00M
Non-Operating Interest Income
10.00M 22.00M 107.00M 29.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
464.00M 272.00M 387.00M 325.00M
Interest Expense Growth
+32.95% -41.38% +42.28% -16.02%
Gross Interest Expense
464.00M 272.00M 387.00M 325.00M
Interest Capitalized
- - - -
-
Pretax Income
1.14B 1.99B 2.28B 3.38B
Pretax Income Growth
+6.04% +73.97% +14.96% +48.33%
Pretax Margin
+9.00% +13.94% +13.63% +16.86%
Income Tax
443.00M 393.00M 436.00M 493.00M
Income Tax - Current - Domestic
69.00M 204.00M 342.00M 264.00M
Income Tax - Current - Foreign
381.00M 116.00M 184.00M 241.00M
Income Tax - Deferred - Domestic
(124.00M) (104.00M) (182.00M) (119.00M)
Income Tax - Deferred - Foreign
117.00M 177.00M 92.00M 107.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
698.00M 1.59B 1.85B 2.89B
Minority Interest Expense
- (1.00M) (8.00M) (6.00M)
Net Income
698.00M 1.59B 1.85B 2.90B
Net Income Growth
-32.88% +128.22% +16.38% +56.31%
Net Margin Growth
+5.50% +11.19% +11.07% +14.44%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
698.00M 1.59B 1.85B 2.90B
Preferred Dividends
- - 55.00M 23.00M
-
Net Income Available to Common
642.00M 1.57B 1.85B 2.90B
EPS (Basic)
0.4488 1.0805 1.2593 1.9576
EPS (Basic) Growth
-35.19% +140.75% +16.55% +55.45%
Basic Shares Outstanding
1.43B 1.45B 1.47B 1.48B
EPS (Diluted)
0.4459 1.0728 1.2471 1.9391
EPS (Diluted) Growth
-35.09% +140.59% +16.25% +55.49%
Diluted Shares Outstanding
1.44B 1.46B 1.49B 1.49B
EBITDA
2.96B 3.38B 3.90B 5.44B
EBITDA Growth
-1.82% +14.09% +15.61% +39.32%
EBITDA Margin
+23.34% +23.71% +23.31% +27.09%

Snapshot

Average Recommendation BUY Average Target Price 102.188
Number of Ratings 37 Current Quarters Estimate 0.792
FY Report Date 03 / 2026 Current Year's Estimate 3.469
Last Quarter’s Earnings 0.80 Median PE on CY Estimate N/A
Year Ago Earnings 3.06 Next Fiscal Year Estimate 3.919
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 25 25 31 30
Mean Estimate 0.79 0.87 3.47 3.92
High Estimates 0.85 0.90 3.72 4.00
Low Estimate 0.78 0.83 3.40 3.84
Coefficient of Variance 2.04 1.88 1.54 1.02

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 29 30 29
OVERWEIGHT 7 7 5
HOLD 1 1 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Boston Scientific Corp. - BSX

Date Name Shares Transaction Value
Jul 31, 2025 Yoshiaki Fujimori Director 2,081 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $106.99 per share 222,646.19
Jul 29, 2025 Edward J. Ludwig Director 18,479 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $106.03 per share 1,959,328.37
Mar 25, 2025 Vance Ronald Brown SVP, GC and Corp. Secretary 41,019 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $100.85 per share 4,136,766.15

Boston Scientific Corp. in the News